Compare IDEXX Laboratories, Inc. (IDXX) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Smith & Nephew plc — how do they compare? IDEXX Laboratories, Inc. trades at $518.98 (market cap $40.43B), while Smith & Nephew plc trades at $27.13 (market cap $11.10B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.6× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Smith & Nephew plc for 121 Days on average.
| IDXX | SNN | |
|---|---|---|
Market Cap | $40.43B | $11.10B |
Volume | 692,164 | 1,051,703 |
Sector | Health | Health |
52-Week High | $766.68 | $37.17 |
52-Week Low | $504.70 | $26.42 |
Typical Hold Time | 46 Days | 121 Days |
Enterprise Value | $41.32B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
